128 related articles for article (PubMed ID: 37404066)
1. Incremental cost burden among patients with severe uncontrolled asthma in the United States.
Burnette A; Wang Y; Rane PB; Chung Y; Princic N; Park J; Llanos JP; Lindsley AW; Ambrose CS
J Manag Care Spec Pharm; 2023 Jul; 29(7):825-834. PubMed ID: 37404066
[No Abstract] [Full Text] [Related]
2. The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma-based severity levels: Insights from a large US commercial and managed Medicaid population.
Pollack M; Gandhi H; Tkacz J; Lanz M; Lugogo N; Gilbert I
J Manag Care Spec Pharm; 2022 Aug; 28(8):881-891. PubMed ID: 35708342
[No Abstract] [Full Text] [Related]
3. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
4. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
5. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
[TBL] [Abstract][Full Text] [Related]
6. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
7. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
8. Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.
Vu M; Duhig AM; Tibrewal A; Campbell CM; Gaur A; Salomon C; Gupta A; Kruse M; Taraman S
J Manag Care Spec Pharm; 2023 Apr; 29(4):378-390. PubMed ID: 36989447
[No Abstract] [Full Text] [Related]
9. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
[No Abstract] [Full Text] [Related]
10. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K
J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101
[No Abstract] [Full Text] [Related]
11. Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.
Xing S; Batt K; Kuharic M; Bullano M; Caicedo J; Chakladar S; Markan R; Farahbakhshian S
J Manag Care Spec Pharm; 2023 Jun; 29(6):626-634. PubMed ID: 37276033
[No Abstract] [Full Text] [Related]
12. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
13. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
14. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
Parasuraman S; Thiel E; Park J; Teschemaker A
J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
[TBL] [Abstract][Full Text] [Related]
15. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
16. Economic Burden of Illness in Adult Patients with Nocturia.
Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
[TBL] [Abstract][Full Text] [Related]
17. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population.
Chung H; Crowe CL; Kong SX; Singh R; Farej R; Elliott J; Williamson T; Willey VJ
J Manag Care Spec Pharm; 2023 Jan; 29(1):80-89. PubMed ID: 36580126
[No Abstract] [Full Text] [Related]
18. Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.
Evans KA; Pollack M; Portillo E; Strange C; Touchette DR; Staresinic A; Patel S; Tkacz J; Feigler N
J Manag Care Spec Pharm; 2022 Dec; 28(12):1366-1377. PubMed ID: 36427341
[No Abstract] [Full Text] [Related]
19. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer.
West H; Hu X; Zhang S; Song Y; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
J Manag Care Spec Pharm; 2023 Jul; 29(7):749-757. PubMed ID: 37404067
[No Abstract] [Full Text] [Related]
20. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
